Cargando…

Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review

Type 1 interferons, especially interferon-beta, has been reported to be effective in COVID-19 patients in multiple randomized controlled trials. The aim of our meta-analysis and systematic review is to assess efficacy of subcutaneous IFN-beta in regards to mortality and discharge rate. Prospective,...

Descripción completa

Detalles Bibliográficos
Autores principales: Asif, Abuzar A., Hussain, Habiba, Senthil Kumaran, Sriviji, Syed, Salman B., Vanka, Varun, Tharoor, Manisha, Rangwala, Umme Salma, Rathore, Urvashi, Singhal, Malay, Chatterjee, Tulika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604440/
https://www.ncbi.nlm.nih.gov/pubmed/34804386
http://dx.doi.org/10.1080/20009666.2021.1984644
_version_ 1784601961217130496
author Asif, Abuzar A.
Hussain, Habiba
Senthil Kumaran, Sriviji
Syed, Salman B.
Vanka, Varun
Tharoor, Manisha
Rangwala, Umme Salma
Rathore, Urvashi
Singhal, Malay
Chatterjee, Tulika
author_facet Asif, Abuzar A.
Hussain, Habiba
Senthil Kumaran, Sriviji
Syed, Salman B.
Vanka, Varun
Tharoor, Manisha
Rangwala, Umme Salma
Rathore, Urvashi
Singhal, Malay
Chatterjee, Tulika
author_sort Asif, Abuzar A.
collection PubMed
description Type 1 interferons, especially interferon-beta, has been reported to be effective in COVID-19 patients in multiple randomized controlled trials. The aim of our meta-analysis and systematic review is to assess efficacy of subcutaneous IFN-beta in regards to mortality and discharge rate. Prospective, retrospective and randomized controlled trials were included. Primary outcomes measured were 28-day mortality and discharge rate. Secondary outcomes measured were mean hospital stay and post-intervention intubation rate. A thorough literature search was conducted in Medline, PubMed, Ovid journals, Google Scholar, and Cochrane Central Register of Controlled Trials & Database of Systematic Reviews from 1 April 2020 to 28 February 2021. Relative risk was calculated using both the Mantel–Haenszel method (fixed-effects model) and DerSimonian Laird method (random effects model). The heterogeneity among studies was tested using Cochran’s Q test, based upon inverse variance weights. 7 studies were included in the meta-analysis and systematic review. The IFN-beta group did not improve the 28-day mortality (RR = 1.276; 95% CI: 1.106–1.472, p = 0.001) or the discharge rate (RR = 0.906; 95% CI = 0.85–0.95, p = < 0.001). The mean hospital stay was 11.95± 2.5 days in the interferon-beta group and 11.43 ± 3.74 days in the traditional treatment group. Likewise, interferon-beta did not add any advantage to post-intervention intubation rate (RR = 0.92; 95% CI = 0.7841–1.0816, p = 0.3154). Our findings revealed that use of subcutaneous interferon-beta is futile in COVID-19.
format Online
Article
Text
id pubmed-8604440
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-86044402021-11-20 Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review Asif, Abuzar A. Hussain, Habiba Senthil Kumaran, Sriviji Syed, Salman B. Vanka, Varun Tharoor, Manisha Rangwala, Umme Salma Rathore, Urvashi Singhal, Malay Chatterjee, Tulika J Community Hosp Intern Med Perspect Research Article Type 1 interferons, especially interferon-beta, has been reported to be effective in COVID-19 patients in multiple randomized controlled trials. The aim of our meta-analysis and systematic review is to assess efficacy of subcutaneous IFN-beta in regards to mortality and discharge rate. Prospective, retrospective and randomized controlled trials were included. Primary outcomes measured were 28-day mortality and discharge rate. Secondary outcomes measured were mean hospital stay and post-intervention intubation rate. A thorough literature search was conducted in Medline, PubMed, Ovid journals, Google Scholar, and Cochrane Central Register of Controlled Trials & Database of Systematic Reviews from 1 April 2020 to 28 February 2021. Relative risk was calculated using both the Mantel–Haenszel method (fixed-effects model) and DerSimonian Laird method (random effects model). The heterogeneity among studies was tested using Cochran’s Q test, based upon inverse variance weights. 7 studies were included in the meta-analysis and systematic review. The IFN-beta group did not improve the 28-day mortality (RR = 1.276; 95% CI: 1.106–1.472, p = 0.001) or the discharge rate (RR = 0.906; 95% CI = 0.85–0.95, p = < 0.001). The mean hospital stay was 11.95± 2.5 days in the interferon-beta group and 11.43 ± 3.74 days in the traditional treatment group. Likewise, interferon-beta did not add any advantage to post-intervention intubation rate (RR = 0.92; 95% CI = 0.7841–1.0816, p = 0.3154). Our findings revealed that use of subcutaneous interferon-beta is futile in COVID-19. Taylor & Francis 2021-11-15 /pmc/articles/PMC8604440/ /pubmed/34804386 http://dx.doi.org/10.1080/20009666.2021.1984644 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of Greater Baltimore Medical Center. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Asif, Abuzar A.
Hussain, Habiba
Senthil Kumaran, Sriviji
Syed, Salman B.
Vanka, Varun
Tharoor, Manisha
Rangwala, Umme Salma
Rathore, Urvashi
Singhal, Malay
Chatterjee, Tulika
Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title_full Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title_fullStr Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title_full_unstemmed Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title_short Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title_sort efficacy of subcutaneous interferon-beta in covid-19: a meta-analysis and systematic review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604440/
https://www.ncbi.nlm.nih.gov/pubmed/34804386
http://dx.doi.org/10.1080/20009666.2021.1984644
work_keys_str_mv AT asifabuzara efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview
AT hussainhabiba efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview
AT senthilkumaransriviji efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview
AT syedsalmanb efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview
AT vankavarun efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview
AT tharoormanisha efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview
AT rangwalaummesalma efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview
AT rathoreurvashi efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview
AT singhalmalay efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview
AT chatterjeetulika efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview